Haisco(SZ:002653) Ge Long Hui A P P·2025-09-03 08:15Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of HSK47388, a drug developed for the treatment of autoimmune diseases [1] Group 1: Drug Development - HSK47388 is an orally administered, potent, and highly selective drug [1] - Preclinical studies have shown significant dose-dependent efficacy in rat models of enteritis [1] - The drug demonstrates good tolerability and a large safety window, indicating strong development potential [1] Group 2: Market Implications - The clinical trial application represents a new indication for HSK47388 in the field of autoimmune diseases [1] - The drug is expected to provide a new treatment option for patients suffering from autoimmune diseases [1]